FDA Warns NOVARX Over Compounded GLP-1 Labels and "FDA Approved Pharmacies" Claim
On June 8, 2026, FDA issued a warning letter to Nova Vascular LLC dba NOVARX after a March 2026 review of novarx.co, which offers compounded semaglutide and tirzepatide products. FDA says pictured labels identify "NOVA RX" as if it were the compounder "when in fact it is not," and cites claims of "access to the same active ingredient found in Ozempic" and sourcing from "FDA Approved Pharmacies" — wording FDA calls "false and misleading" because it does not approve pharmacies. FDA requested a written response within 15 business days.
What this meansFDA does not approve or license compounding pharmacies, so "FDA-approved pharmacy" language on a provider's site is worth questioning — how a provider describes its pharmacy partners says a lot about how carefully it operates.
Source: FDA original ↗